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Breast cancer, one of the most common cancers in women, has various treatment modalities. 
Neoadjuvant therapy (NAT) has been used in many clinical trials because it is easy to evaluate the 
treatment response to therapeutic agents in a short time period; consequently, NAT is currently a 
standard treatment modality for large-sized and locally advanced breast cancers, and its use in 
early-stage breast cancer is becoming more common. Thus, chances to encounter breast tissue 
from patients treated with NAT is increasing. However, systems for handling and evaluating such 
specimens have not been established. Several evaluation systems emphasize a multidisciplinary 
approach to increase the accuracy of breast cancer assessment. Thus, detailed and systematic 
evaluation of clinical, radiologic, and pathologic findings is important. In this review, we compare 
the major problems of each evaluation system and discuss important points for handling and 
evaluating NAT-treated breast specimens.
Key Words: Breast neoplasms; Neoadjuvant therapy; Pathologic response evaluation
Received: January 5, 2016
Revised: February 1, 2016
Accepted: February 2, 2016
Corresponding Author
Ja Seung Koo, MD
Department of Pathology, Severance Hospital, 
Yonsei University College of Medicine,  





Journal of Pathology and Translational Medicine 2016; 50: 173-180
http://dx.doi.org/10.4132/jptm.2016.02.02
▒ REVIEW ▒
Application of neoadjuvant therapy (NAT) has become a 
more common breast cancer treatment due to the diversity and 
rapid development of associated therapeutic agents. NAT is 
currently established as a standard therapeutic approach for pa-
tients with large (> 2 cm) and locally advanced breast cancer.1 
In addition, trials for NAT use in early-stage breast cancer are 
gradually increasing.2 Although there is no gain in survival ben-
efit from NAT for breast cancer, it does offer several significant 
advantages over other modalities: (1) Response efficiency to a new 
therapeutic agent can be assessed3-5 because it is easy to detect a 
treatment response in a relatively short time period. In this re-
spect, many clinical trials have been designed to evaluate NAT.6 
(2) Patients with large cancers who show a response to NAT can 
undergo breast-conservation surgery.7,8 (3) The degree of re-
sponse to NAT can play a role as a prognostic factor; one study 
reported that the rate of local recurrence depends on the extent 
of residual tumor after NAT.9 Given the potential benefits, ex-
act assessment of breast specimens after NAT is very important. 
However, standard guidelines for pathologic evaluation of 
breast specimens after NAT have not been established.9-14 Here-
in, we offer a concise review of the various standard guidelines 
for pathologic assessment of breast cancer specimens after NAT.
EVALUATION OF BREAST CANCER SPECIMENS 
AFTER NEOADJUVANT THERAPY
Specimen handling 
Identification of the tumor bed is important for the handling 
of breast specimens after NAT. Close examination of fresh speci-
mens cut into 5-mm sections or smaller is required for identifi-
cation of the tumor bed. However, some cases require extensive 
sampling because of uncertainty in the gross identification of 
tumor bed. There have been attempts to insert metallic clips 
while conducting breast core biopsy for easy recognition of the 
tumor bed.15-18 However, this method cannot locate the tumor 
bed accurately because the inserted metallic clip shifts over time.19 
Some guidelines suggest that small specimens (< 5 cm at the 
widest diameter or < 30 g) should be thinly sectioned and sub-
mitted in their entirety so that the specimens can be reintegrat-
ed upon histologic evaluation. However, these methods have lim-
itations in that samples for research use cannot be secured.20 It 
is crucial to select representative sections when dealing with large 
specimens, such as those from a large lumpectomy or mastecto-
my. The important goal in specimen selection is to identify the 
area that correlates best with clinical and radiologic findings. 
This area, which is known as the pretreatment area, should com-
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prise grossly identifiable tumor bed, a metallic clip, and peritu-
moral tissue.20 After slicing surgical specimens into ≤ 5-mm 
sections, the cross-section that includes the largest pretreatment 
area should be selected for sampling. The extent of tissue sam-
pling varies according to guidelines: one or two tissue blocks 
from every 1 cm of pretreatment tumor13,20 or 10 blocks at least 
from an entire specimen.4 Because histologic patterns of residual 
post-NAT breast cancer tumors are diverse, different sampling 
methods can yield different evaluation results (Fig. 1), potentially 
resulting in sampling error. Even so, submission of large surgical 
samples in their entirety is not recommended because it is inef-
ficient and offers little information despite the intensive sam-
pling effort required.21 Thus, the extent of tissue sampling 
should be optimized and determined on a case-by-case basis con-
sidering clinical, macroscopic, and radiologic features. However, 
it is important, when creating sample specimens, to provide an-
notations and photographs of each tissue block to clarify the or-
igin of tissue sections; this enables the pathologists conducting 
evaluations to identify correlations between macroscopic and his-
tologic features.20,21 Also, exact descriptions, including the size of 
any grossly visible tumor beds and distances from resection mar-
gins, should be recorded.
Microscopic pathologic report
Pathologic variables that describe surgical breast cancer spec-
imens that were not exposed to NAT are also important for post-
NAT specimen. However, several factors should be taken into ac-
count, due to the diversity of evaluation systems for post-NAT 
breast cancer, including differences in major variables of each 
evaluation system and histologic factors causing post-NAT 
changes (Table 1). A summary of the pathologic reports for breast 
cancer after NAT is provided in Table 2.
Histologic tumor subtype and grade
In principle, the method to evaluate histologic subtype and 
tumor grade in breast cancer patients who received NAT is the 
same as that used for patients with non-neoadjuvant cancer. How-
ever, it is necessary to consider that NAT can affect histologic ar-
chitecture, nuclear features, and tumor mitosis.5,22-24 Thus, some 
cases require comparison with pretreatment biopsy findings. 
Tumor size and extent
There are many potential variables that can be used for as-
sessing tumor size/extent in breast cancer patients who received 
NAT. Variable relevance depends on which tumor-response eval-
uation system is being used, because each system offers a differ-
ent definition of significant tumor size. For example, the largest 
contiguous focus of the invasive cancer is the most important fac-
tor in determining ypT stage in ypTNM system.10 Contrarily, 
the two dimensions of the largest residual area of remaining in-
vasive cancer are most important according to the Residual 
Cancer Burden (RCB) system.14 For the RCB system, however, 
the residual invasive cancer does not need to be contiguous, lead-
ing to a discrepancy in perceived tumor size between the two 
systems.14 The largest discrepancies in tumor size/extent due to 
the differences in measurement methods were observed when 
the tissue response pattern after NAT manifested as a scattered 
pattern (Fig. 2). 
Tumor cellularity 
Though NAT can affect several parameters of breast cancer, 
tumor cellularity is one of the most representative factors.25 Tu-
mor cellularity is not always recorded in pathologic reports be-
cause it is important in some tumor-response systems11,13,14 but 
not in others.10,12,26 There are several factors that should always 
be considered when evaluating tumor cellularity. The first fac-
tor is the comparison of cellularity in pre- and post-treatment 
specimens (Fig. 3). Differences between pre- and post-treatment 
cellularity are important for some tumor-response systems;11 
however, pretreatment cellularity is not considered in the RCB 
system.14 The second factor is tumor heterogeneity. Because re-
sidual tumor cellularity can appear heterogeneous after NAT, 
extensive tissue sampling should be performed. However, the 
majority of systems do not specifically include the cellularity of 
Fig. 1. Differences in tumor evaluation results according to tissue 
sampling method in breast cancer after neoadjuvant therapy. In 
this example, when sampling in the area indicated by the blue rect-
angle, aspects of the residual tumor (e.g., tumor size/extent) are 
observed and appear different from the sampling area indicated by 
the purple rectangle, where heterogeneity of the residual tumor 
and tumor bed is present.
Tumor bed
Invasive cancer cell cluster
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residual heterogeneous tumors, except for the RCB system, 
which recommends mentioning the average tumor cellularity.14
Lymphovascular invasion
Lymphovascular invasion (LVI) is documented in most patho-
logic reports because it is a significant prognostic factor in non-
neoadjuvant breast cancer.27,28 Though there are insufficient data 
on whether LVI is independently significant in neoadjuvant spec-
imens, it should still be mentioned in pathologic reports.20 Duc-
tal carcinoma in situ (DCIS) and LVI are defined as resistant breast 
cancer components after NAT.22 Therefore, in some situations, 
the only residual after NAT is tumor emboli in lymphovascular 
space, with no residual tumor in the breast parenchyma (Fig. 4).29 
According to these guidelines, researchers have recommended 
that such cases not be regarded as pathologic complete response 
(pCR).20 Consequently, several LVI measurement methods have 
Table 1. Comparison of pathologic response evaluation system for breast cancer after neoadjuvant therapy
System Included variable Definition of pCR Category status Reference 
AJCC (y) Size of invasive carcinoma No invasive carcinoma 
  in breast and lymph node
Stage 0 Boughey
  et al.8
Lymph nose status (the number of 
  metastatic lymph node and size 




B-18 Treatment effect in invasive carcinoma No invasive carcinoma 
  in breast and lymph node
No pathologic response Diaz
  et al.24
Lymph nose status (the number of 
  metastatic lymph node and size 
  of metastatic deposit)
Pathologic partial response
Pathologic complete response
Miller-Payne Presence of invasive carcinoma No invasive carcinoma
  in breast
Grade 1: no change or some minor alteration in 
  individual malignant cells, but no reduction in 
  overall cellularity 
Mamounas
  et al.9
Tumor cellularity Grade 2: a minor loss of tumor cells, but overall 
  high cellularity; up to 30% reduction of cellularity
Grade 3: between an estimated 30% and 90% 
  reduction in tumor cellularity
Grade 4: a marked disappearance of more than 
  90% of tumor cells such that only small clusters 
  or widely dispersed individual cells remain
Grade 5: no invasive malignant cells identifiable in 
  sections from the site of the tumor
MNPI Size of invasive carcinoma No invasive carcinoma 
  in breast and lymph node
MNPI=0.2×tumor size+lymph node stage+MSBR 
  grade
Carey 
  et al.10
Tumor grade Lymph node state: 1, node negative; 2, 1-3 positive; 
  3, ≥4 positive
Lymph nose status (the number of 
  metastatic lymph node)
Pinder Tumor proportion (%) in remaining breast No invasive carcinoma 
  in breast and lymph node
Complete pathologic response Ogston 
  et al.11
Lymph nose status (presence of 
  evidence of response)
Partial response to therapy
  < 10% of tumor remaining
  10%–50% of tumor remaining
  > 50% of tumor remaining
No evidence of response
RCB Size of tumor bed in two dimension No invasive carcinoma 
  in breast and lymph node
RCB 0: no residual disease Abrial 
  et al.12
Tumor cellularity RCB 1: minimal residual disease
Lymph node status (the number of 
  metastatic lymph node and size 
  of metastatic deposit)
RCB 2: moderate residual disease
RCB 3: extensive residual disease
pCR, pathologic complete response; AJCC, American Joint Committee on Cancer; MNPI, Modified scores from Nottingham Prognostic Index; MSBR grade, 
Modified Scarff Bloom Richardson grade; RCB, residual cancer burden.
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been suggested, including measurement according to size20 or 
using semi-quantitative methods (focal or extensive).30
Surgical margins 
Evaluation of resection margins is identical to that for non-
neoadjuvant breast cancer specimens. Careful examination is re-
quired for evaluation of resection margins in neoadjuvant speci-
mens because grossly invisible residual tumors or multiple sc-
attered microscopic tumor foci are common. Furthermore, when 
the resection margin involves the tumor bed, it should be docu-
mented in the pathological report.
Evaluation of the axillary lymph node after NAT
The evaluation method for axillary lymph nodes is the same as 
that for non-neoadjuvant cases. Generally, all lymph nodes are 
sectioned into 2-mm intervals and sampled in their entirety for 
microscopic evaluation. Sometimes lymph nodes with complete 
treatment response are observed under microscopic evaluation 
for characteristic features, such as fibrous scarring, lymphocytic 
depletion, or histiocytic aggregation, without any identifiable 
tumor cell clusters (Fig. 5). If lymph nodes with these features 
are identified during microscopic evaluation, the total number 
observed should be noted in the pathologic report.31 When met-
astatic deposits are observed, the size of the largest metastatic 
tumor and presence/absence of extranodal extension should be 
recorded. It is difficult to measure the size of the largest meta-
static tumor when the treatment response is accompanied by me-
tastasis. In cases with multiple singly scattered tumor cells that 
involve the entire lymph node and when the treatment response 
is not accompanied by fibrosis, the size of the metastatic tumor 
is determined by measuring the size of the largest cell cluster. 
Some guidelines recommend measuring the sizes of the tumor 
cells and intervening stroma—not the largest cell cluster—when 
accompanied by a tumor response; consensus for these measure-
ments has not been established among the various evaluation 
systems.20 Thus, when metastatic deposits are observed during 
microscopic evaluation, conditions such as macrometastasis, mi-
crometastasis, and isolated tumor cells can be altered by chang-
es in the sizes of metastatic deposits according to applied systems. 
However, residual disease in the lymph nodes are not considered 
pCR in most systems.10,20
Table 2. Example of pathologic report form in breast cancer after 
neoadjuvant therapy
Pathologic report form 
Gross finding
Residual identified tumor: yes/no
Quadrant of tumor 
Multifocality: yes/no
Size of residual tumor: xx mm
Identified clip of marker: yes/no
Microscopic finding
Histologic diagnosis: invasive carcinoma, NST
Histologic grade: I/II/III (tubule score–nuclear grade–mitosis score)
Size of residual tumor bed: x mm
Size of the largest residual invasive carcinoma: x mm
Residual tumor cellularity: %
Lymphovascular invasion: absent/present
DCIS component: yes/no
  Total tumor size including DCIS: x mm
  Extensive intraductal component: yes/no
  Type: cribriform/micropapillary/solid/papillary
  Nuclear grade: low/intermediate/high
  Necrosis: absent/present (focal/commedo)
ER/PR/HER-2 status: optional
Resection margin
Invasive carcinoma: absent/present; distance to the closest margin
DCIS: absent/present; distance to the closest margin
Tumor bed: absent/present
Lymph node status
Number of sentinel lymph nodes
Number of total axillary lymph nodes
Number of lymph nodes with macrometastasis 
  Size of largest metastasis: mm
Number of lymph nodes with micrometastasis 
Number of lymph nodes with isolated tumor cells
Number of lymph nodes with histologic evidence of treatment 
  response but no tumor cells
Extracapsular extension: yes/no 
NST, no specific type; DCIS, ductal carcinoma in situ; ER, estrogen recep-
tor; PR, progesterone receptor; HER-2, human epidermal growth factor re-
ceptor-2.
Fig. 2. Comparison of tumor size/extent measurements between 
the Residual Cancer Burden (RCB) and ypTNM systems. In the 
RCB system, the largest cross-section among areas with invasive 
tumors is measured in two dimensions (a). In the ypTNM system, 
the largest contiguous invasive carcinoma foci are measured (b).
Tumor bed
Invasive cancer cell cluster
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Pathologic complete response
Though each system that evaluates treatment responses to 
NAT has a unique definition of pCR, all systems record whether 
the patient has invasive carcinoma and whether it is identified in 
the breast parenchyma.9-14 Significant differences among these 
evaluation systems are based on the inclusion or exclusion of 
DCIS and axillary lymph node status. Thus, description of DCIS 
and axillary lymph node status should always be included in 
pathologic reports because the treatment response evaluation sys-
tems differ across institutions.
Re-evaluation of biomarkers in breast cancer after NAT
Estrogen receptor (ER), progesterone receptor (PR), and hu-
man epidermal growth factor receptor-2 (HER-2), which are rep-
resentative biomarkers of breast cancer, should be used for eval-
uating invasive breast cancer; however, there is no consensus on 
whether ER, PR, and HER-2 status should be re-evaluated in 
breast cancer patients who received NAT. Different guidelines 
suggest different processes based on core biopsy results, because 
ER, PR, and HER-2 statuses after NAT are evaluated based on 
the biomarker status of pretreatment core biopsy. If ER, PR, and 
HER-2 statuses from pre-treatment core biopsy are all positive, 
there will be no changes in status for most patients; thus, re-
evaluation is generally not recommended. However, re-evalua-
tion is considered necessary in the following circumstances: (1) 
negative or equivocal results in core biopsy, (2) only DCIS or 
insufficient invasive carcinoma in core biopsy, (3) core biopsy 
performed at another institute, and (4) no treatment response.20,21 
Additionally, re-evaluation should be performed when the pa-
tient is enrolled in a clinical trial protocol or when ER, PR, or 
Fig. 3. Comparison of tumor cellularity between pre-neoadjuvant therapy (NAT) and post-NAT. In comparison with the tumor cellularity of a 
pre-NAT biopsy (A), the tumor cellularity observed in a post-NAT surgical specimen (B) is significantly low.
A B
Fig. 4. Residual tumor emboli in lymphovascular space after neoadjuvant therapy (NAT) (A, B). There are only tumor emboli in the lympho-
vascular space after NAT.
A B
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HER-2 status is unknown.
CONCLUSIONS
The number of existing post-NAT breast cancer specimens 
has recently increased because NAT is now established as an ef-
fective treatment approach for patients with large or locally ad-
vanced breast cancer and for cases of early-stage breast cancer. 
However, guidelines for pathologic evaluation of breast cancer 
after NAT have not been established; instead, there are several 
evaluation systems, each with different major main-effect vari-
ables. Moreover, from macroscopic examination to microscopic 
evaluation, there are several obstacles to pathologic evaluation 
of neoadjuvant breast cancer because there is a diverse range of 
histologic responses to NAT. Pathologic evaluation of residual 
disease is the most essential component of post-NAT breast can-
cer evaluation. Thus, the evaluation should be conducted based 
on close comparisons and correlations between clinical, radio-
logic, and pathologic findings.
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